Evaluation of Treatment With Interferon, Octreotide, or Their Combination in Patients With Zollinger-Ellison Syndrome and Progressive Metastatic Non-B Islet Cell Neoplasm

Inclusion Criteria

- INCLUSION CRITERIA

Subjects selected for this study will be patients with Zollinger-Ellison syndrome who are
being evaluated under the protocol entitled "Diagnostic evaluation of patients with
suspected abnormalities of gastric secretion" (80-DK-123). To be entered into the study a
patient must meet each of 3 criteria:

1. histologically proven gastrinoma;

2. evidence of metastatic tumor by one or more of angiography, ultrasound, computerized
axial tomography, bone scan or octreoscan;

3. progression of tumor size during the preceding 6 months as assessed by repeated
imaging studies.

EXCLUSION CRITERIA

For treatment with interferon-(alpha):

1. Congestive heart failure

2. Proteinuria, 3 + or greater

3. Creatinine clearance less than 30 ml/min

4. Platelet count less than 30 x 10(9)/1

5. White blood count less than 4 x 10(9)/1

6. Bilirubin greater than 3 mg/dl

7. Positive test for HIV antibody

8. Pregnancy

For treatment with octreotide:

1. Presence of cholelithiases